基于框架核酸功能化液滴芯片的外泌体富集及大肠癌潜在标志物lncRNA OSER1-AS1即时检验的研究

大肠癌复发转移是导致高死亡率的主因，发现可预测大肠癌早期复发的分子标志物并建立精准检验新技术是实验诊断领域热点问题。在课题组前期已建立可预测大肠癌复发转移的组织分子预测模型基础上，申请人发现血清外泌体lncRNA OSER1-AS1表达变化可作为独立预后因子用于大肠癌复发转移及化疗敏感性预测，可望成为指导临床治疗及预后评估的无创分子标志物。申请人将围绕“血清外泌体高效特异富集、无损释放及特定lncRNA高灵敏度精准检测”这一关键科学问题，在融合医学、化学、物理学和材料学等多学科交叉的基础上，建立基于框架核酸功能化液滴芯片的血清外泌体捕获及lncRNA OSER1-AS1即时检验新方法，为大肠癌复发及预后评估提供新的技术平台。通过前瞻性研究证实血清外泌体lncRNA OSER1-AS1在预测大肠癌复发中的临床应用价值，为进一步寻找治疗大肠癌特异性靶点、实现大肠癌个体化治疗提供新的策略和思路。

Recurrence and metastasis of colorectal cancer is the main cause of death of patients. Finding non-invasive molecular markers that can predict the early recurrence of colorectal cancer and establishing a new technique for accurate testing are hot issues in the field of experimental diagnostics. We have recently found that the change of serum exosomes lncRNA OSER1-AS1 level can predict the sensitivity of chemotherapy and the progression of disease. It is expected to be a new non-invasive test index to guide the clinical treatment and prognosis evaluation of colorectal cancer. Based on the key scientific issues of serum exosomes high efficiency specific enrichment and nondestructive release and highly sensitive and accurate detection of specific lncRNA, a framework nucleic acid functional droplet chip-based will be established for the serum exosomes enrichment and lncRNA OSERA-AS1 testing at the point of care. This method combines multidisciplinary cross-cutting content such as medicine, chemistry, physics and materials to provide a new technology platform for the assessment of recurrence and prognosis of colorectal cancer. The clinical value of serum exosomes lncRNA OSER1-AS1 in the recurrence of colorectal cancer will be confirmed by prospective study. To provide new strategies and ideas for further finding specific targets for the treatment of colorectal cancer and individualized treatment for colorectal cancer.